Schizophrenia Player BioXcel's Drug Faces Funding Headwinds, Analyst Downgrades Stock

Truist downgraded BioXcel Therapeutics Inc BTAI from Buy to Hold, citing significant near-term funding and clinical development headwinds

Wednesday, the company updated recent developments with its late-stage clinical programs and patent portfolio for Igalmi (dexmedetomidine) sublingual film, including the scheduled FDA meeting to discuss the TRANQUILITY and SERENITY III programs.

The analyst writes that the cash runway is a significant risk. Truist said it would be more confident in BTAI if feedback from Oct/Nov FDA meetings indicates a favorable clinical development path for Igalmi dementia and at-home use label extensions.

Also Read: Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy.

While Truist maintains its optimistic outlook for Igalmi, with the current macroeconomic landscape, investors may not fully recognize its potential. 

Igalmi is a prescription medicine used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults.

Nevertheless, realizing substantial value remains contingent on BTAI's securing sufficient funding for expanding Igalmi into broader indications. 

Price Action: BTAI shares are down 4.34% at $2.53 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsPenny StocksDowngradesHealth CareAnalyst RatingsMoversTrading IdeasGeneralBriefsExpert Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!